Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: biphasic insulin aspart 30Drug: biphasic insulin aspart 70
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 59
- Registration Number
- NCT01538511
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Paediatric Subjects - Special Survey
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT01538576
Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 211
- Registration Number
- NCT01536626
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Alphen a/d Rijn, Netherlands
Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33010
- Registration Number
- NCT01536600
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of
The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- Drug: liraglutideDrug: placebo
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 45
- Registration Number
- NCT01536665
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 454
- Registration Number
- NCT01536639
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
Post Marketing Surveillance Study of Biphasic Insulin Aspart 30
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5346
- Registration Number
- NCT01536613
Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4994
- Registration Number
- NCT01536652
Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- Drug: biphasic insulin aspart 30Drug: biphasic insulin aspart 50Drug: biphasic insulin aspart 70Drug: insulin aspart
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01536028
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 34
- Registration Number
- NCT01530048
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Hvidovre, Denmark
© Copyright 2025. All Rights Reserved by MedPath